How can we minimise the use of regular oral corticosteroids in asthma?

Options to achieve oral corticosteroid (OCS)-sparing have been triggering increasing interest since the 1970s because of the side-effects of OCSs, and this has now become achievable with biologics. The Société de Pneumologie de Langue Française workshop on OCSs aimed to conduct a comprehensive review of the basics for OCS use in asthma and issue key research questions. Pharmacology and definition of regular use were reviewed by the first working group (WG1). WG2 examined whether regular OCS use is associated with T2 endotype. WG3 reported on the specificities of the paediatric area. Key "research statement proposals" were suggested by WG4. It was found that the benefits of regular OCS use in asthma outside episodes of exacerbations are poorly supported by the existing evidence. However, complete OCS elimination couldn't be achieved in any available studies for all patients and the panel felt that it was too early to conclude that regular OCS use could be declared criminal. Repeated or prolonged need for OCS beyond 1 g·year

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: A. Bourdin reports institutional fees for board membership from AstraZeneca, Novartis, GSK, Boehringer Ingelheim, Chiesi, Actelion, Pfizer and Teva, outside the submitted work. Conflict of interest: I. Adcock reports grants from EU-IMI, during the conduct of the study. Conflict of interest: P. Berger reports non-financial support from AstraZeneca, during the conduct of the study; personal fees and non-financial support from AstraZeneca, Sanofi, Circassia and Menarini grants, personal fees and non-financial support from Boehringer Ingelheim, and grants and personal fees from Novartis, outside the submitted work. Conflict of interest: P. Bonniaud reports personal fees and other from Roche, Boehringer, Novartis, personal fees from TEVA and AstraZeneca, and other from Chiesi and Stallergene, outside the submitted work. Conflict of interest: P. Chanson has nothing to disclose. Conflict of interest: C. Chenivesse reports grants and personal fees from AstraZeneca and Novartis, and personal fees from AIR LIQUIDE, ALK Abello, Boehringher Ingelheim, Chiesi, GSK, Sanofi and Teva, outside the submitted work. Conflict of interest: J. de Blic reports institutional fees for board membership from GSK, Boehringer Ingelheim, AstraZeneca, Novartis, Chiesi and Stallergenes, outside the submitted work. Conflict of interest: A. Deschildre reports personal fees from Novartis, TEVA, Stallergenes Greer, AImmune, Zambon, personal fees and other from ALK, GSK, Chiesi, AstraZeneca and DBV technologies, outside the submitted work. Conflict of interest: P. Devillier reports personal fees and non-financial support from AstraZeneca and Boehringer Ingelheim, and personal fees from Chiesi, GlaxoSmithKline, Novartis and Sanofi, outside the submitted work. Conflict of interest: G. Devouassoux reports personal fees from GSK, Astra Zeneca and Novartis, during the conduct of the study. Conflict of interest: A. Didier reports institutional fees for board membership from AstraZeneca, Novartis, GSK, Boehringer Ingelheim, Chiesi and Menarini, outside the submitted work. Conflict of interest: G. Garcia reports institutional fees for board membership from AstraZeneca, Novartis, GSK, Boehringer Ingelheim, Chiesi, Actelio, Pfizer and Teva, outside the submitted work. Conflict of interest: A. Magnan has nothing to disclose. Conflict of interest: Y. Martinat reports institutional fees for board membership from AstraZeneca, Novartis, GSK, Boehringer Ingelheim, Chiesi, Actelio, Pfizer and Teva, outside the submitted work. Conflict of interest: T. Perez reports institutional fees for board membership from Novartis, GSK, Boehringer Ingelheim and Chiesi, grants from AstraZeneca, and fees for travel from Chiesi, AstraZeneca, and Boehringer Ingelheim, outside the submitted work. Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, and personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. Conflict of interest: C. Taillé reports personal fees, non-financial support and other from AstraZeneca and from Novartis, grants, personal fees, non-financial support and other from GSK and Sanofi, and personal fees from Teva, during the conduct of the study. Conflict of interest: P. Val has nothing to disclose. Conflict of interest: P. Chanez reports grants and personal fees from Almirall, Boehringer Ingelheim, ALK, GSK, AstraZeneca, Novartis, Teva and Chiesi, and grants from AMU, outside the submitted work.